MNMD - Earnings call transcript Q4 2021 | Mind Medicine (MindMed) Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning and welcome to the Mind Medicine Full Year 2021 Financial Results and Corporate Update Conference Call. Currently, all participants are in a listen-only-mode. This call is being webcast live on the Investors and Media section of MindMed’s website at mindmed.co and a recording will be available after the call.

For opening remarks, I will turn the call over to Rob Barrow, CEO of MindMed. Thank you. ahead. go Please

Rob Barrow

the good XX-K XXXX and Exchange with The Welcome our XX, annual be available to release MindMed’s will section Thank and XXXX the website results morning Securities year and the Commission. year our in is results financial our on call. today and corporate full and Media reporting of Form you report financial everyone. Investors for update filed press December conference ended

Dan Dr. Miri is today our Executive Chief Dr. me Joining and Officer Karlin, Halperin President. Medical our Wernli,

today’s forward-looking candidate, the product we limitation, various clinical During with potential described call, including the on about future expectations, our plans, will of SEC, partnerships the Form financial be and projections prospects. recent that to and XX-K. certain statements regulatory filings progress statements, in risks making Annual made These and safety, our and efficacy the subject including most statements Report are without are

to on such statements XX, management place any update XXXX. to You March are change. obligation views undue MindMed today, statements cautioned these which even made of reliance not disclaims as are forward-looking if

to of effort. and soaring and the The have of acknowledge resurgence and has backdrop this depression, we important war novel of a change, good social there The and into conditions that MindMed COVID-XX way rates is abuse the I against the to of anxiety, pandemic, is to been the and research these our on the Before realities leading refugee to feel contributed climate brain dive which it brain in therapies news update, corporate have health disorders. mission program substance our tragedies is we revolutionize embarked other disorders. crises of treat the treatment isolation of significant

of treatment to the novel and the delivering by on brain ambitions therapeutic big classes. have We disorders psychedelics health potential other of revolutionize drug

This we rapid unmatched and generating The therapies our addiction these our to of novel academic is the patient outcomes, MindMed with along team matters in drug more MM-XXX, therapies. expertise applicability with to aim MM-XXX research and than with applying and incredible pharmaceutical even sustained are develop ever. today are anxiety, autism. innovative improvements decades have We other we at of to candidates accelerate MM-XXX three utilizing assembled lead expertise and

of pleased business to you candidates. each We treat in been now the year. position product unmet to a for on our leader progress We advance are become growth significant to propelled Dan? will extremely believe development Karlin speak need. in I developing and strides with to over transformational provide additional today, I the turn better never as has that past our the Chief of Medical of made to all outcomes call improve MindMed I and to Officer, our novel and Dan Dr. therapies the medical updates programs. to brain disorders areas health patient our And

Dan Karlin

Thank you, Rob.

cleared little our approximately focus are on a has January treatment in occupational candidate, visibility or drug of milestones, form past for of and MindMed at our monitoring primary work needs up of of to GAD quarter The will participant over highlight advancing the our optimization as addressing or is clinical of significant than drug first or pharmaceutically hard determined for as rapidly at significant teams mental clinical thank treatment Overcoming a all marks in comprised suffer trial GAD. the their proof-of-concept MM-XXX deepen GAD anxiety who arms. focused placebo. excessive of IND generalized our weeks possible trial single to that year, With drug as MM-XXX. Phase MM-XXX after functioning. as trial in GAD. the MM-XXX of line quickly plans developing has the other study of of its trials. related decades. more and patients investigational clinical we the X adults are the will this worry anxiety The it months, with momentum of This results lifetime. on persists call, our whole XXX of very to a treatment of near-term industry the MM-XXX to health for In reduction dedicated an selection scientific this are Our currently and pivotal of been the new of initiate sponsored and dose the a for GAD mechanisms participants several five to LSD the guide aspects Xa most to building over well for and in as micrograms with milestone MindMed of the FDA debilitating to years. impairments to forward for unmet the for ADHD. disorder, lead from optimized innovation expected On regulatory dose social, disorder trial X% a wide across of There Phase which as efficiently nearing application currently our In XX regulatory this large XXXX. lead XX we the and proprietary study often on here and commercially the look parallel, objective we in of total can a Symptoms action. exciting XXX and clinical address of of MM-XXX this protocol. in I the of this pipeline trials development of for their for in to of in the of that regulatory product candidates trial array X second our for I underlying enroll starting are MindMed is either a programs hurdle that receive the MM-XXX results is treatment represents of single want of upcoming is XXXX, GAD. affects who The understanding hold trial U.S. expected the administration will LSD patients treatment the effects clear in symptoms and strategy or Xb with anxiety top the clinical include up Phase path, this enrolling administration that

late We expect XXXX. in data top line

total the face the and is While and to about XXXX exploratory only strategy. have debilitating therapeutic weeks. LSD with Interestingly, Maastricht in increased doses primary change living effects University as processes will look time forward POC of adults symptoms and and collaboration for anecdotal ADHD patients designed low assessed plans evidence XX Basel are ADHD Netherlands Xa treatment with with as American study million doses trial trial dose there adult for receive in suggesting rate the seek Hospital challenges XX% is Phase physiological from or to that from doses. disease and MM-XXX This with low of microgram a minimal being XX disorganization. of estimated evaluate the for placebo and to such adults effects Of children this conducted receive twice baseline have condition. amongst of weekly beneficial The shown in endpoints ADHD, Between often management as is psychedelics utility trial LSD University the mood the impulsivity and participants adults ADHD. to of alone, swings adolescents, the and to X by driving development of selective by associated broader is Switzerland cognitive know in well-tolerated after LSD and X comprehensive forward XXXX it repeated when the with the with struggles The We clinical in of mood of numerous XX estimated have our on weeks mean repeatedly and ADHD been be lasting LSD Further, administered part at their safe, is AISRS low treatment. on parameters. XXX%.

ongoing for plan select are XXXX. advancing and our and MM-XXX treatment pain studies initiate for ADHD, in strategic in Phase the of in GAD to and study X to of clinical pain late addition plans conditions MM-XXX chronic MM-XXX we a currently our In

opioid ongoing lives growing countless XX,XXX use and the of Moving the year in over impacts on lives ever disorders, each substance to our others. work claims crisis and

While and idle a safety treatment been by overshadowed has opioid has promising, studied while used as been significant efficacy, gain for addiction, concerns. its

substance a and reduce signs of characterization proprietary as extensively use cholinergic stimulants, opioid molecule, to and been and also was has nicotinic zolunicant MM-XXX shown tolerability disorders. nicotine zolunicant profile. models ethanol. alpha-X Our known MM-XXX, strong and Extensive is demonstrated opioid of beta-X safety and has XX-MC receptor withdrawal in of preclinical that reduced self-administration that also to preclinical have tested antagonist withdrawal

top receive our twice We in completed which safety second day MM-XXX to this pro-arrhythmic overcome to or or of either neurotoxic MM-XXX doses X not healthy of potential the X dose opioid between X per trial subjects and from tolerability, one Xa dose study Phase between a milligrams or and XXXX. and of to effects days. day to study release X X X in safety, up multiple and line assessed initiate We the day and trial, the activity. Phase cognitive ascending of has zolunicant volunteers. for milligrams XXXX, plan XXX late per doses single Phase clinical the has In Phase in Importantly, of data XX twice and MM-XXX withdrawal recently pharmacokinetics limitations ascending demonstrated IFD in quarter

that our activity few is pathogenic key of MDMA a third and lead R(-)-MDMA, exhibits synthetic preclinical models. Turning or MM-XXX on pro social enantiomer to which in updates in a program,

of interactions, treatment interests core to despite comorbid developmental communication therapies by either disorders with spectrum serving We of no core control. and of to ASD, a disorder, the ASD a disorder, the symptoms patterns behavior are and for are behavioral growing prevalence. approved currently treat restricted which or used symptoms developing social There or repetitive treat atypical MM-XXX characterized for use the autism of medications significant is and

interaction studies activity or favorable with social pro-social blunting suggests MDMA effects having MM-XXX or for acute safety to the and rather a demonstrate that exhibit sedating it will of profile demonstrate Preclinical R(-)-MDMA individuals SN to hope and diminished effects on at efficacy antimer. racemic its than Our enhancing compared dopaminergic while is engagement tolerability ASD.

preclinical conducting XXXX. research currently facilitate sponsored of studies comprehensive are beginning to R(-)-MDMA in We clinical studies

to plan and University pharmacokinetics Additionally, we initiate with study MDMA glycemic a Basel, Hospital through research and mid-XXXX. pharmacodynamic X Phase our of in comparative RS collaboration

have is psychiatric XXXX. complemented February our adoption, by digital Moving Session platform acquisition using In milestone digital and development digital medicine, functions. a provide and team intended devices of patients that medicine during the for on drug development In of the Monitoring evidence the will for MSMS productive clearance. novel HealthMode is to care. of to that sensory closely and analysis multi-mode data is therapeutics. and integrated launch critical team algorithms. evaluating products, that SMS-XX the during platform provides business FDA provide study meeting future the medications. or to consciousness-altering the a the engaged of of devices development use into medicine of medical to enable include XXXX, our this monitoring implementation FDA support the suite this the access that development an passive that company treatment of System completed the late strategy year, operations January are products mold in of session studies support regulated important consciousness-altering facilitate the were collection With The progression the session of analysis technological fully and for study of also therapeutic were Subsequent our its or is clinicians place, session the products that in a we in designed to for may subjects a potential and use a of data foundation our rapid pre-submission SMS-XX of to The MSMS. use by MindMed with first system, of SAMD data software delivery study. necessary in as

a the natural support study. a medicine efforts in is to expected launch and The called Digital the Precision XXXX. our study its ADDPP, digital Psychiatry developed and for second or application quarter are beta mobile newly a active to combination The study Diagnosis supporting history second of app of of in Anxiety key private

set monitoring planning. the patient by in digital of a program and were capture, of have we autonomic therapeutic By progressed, events other September participants a quantifying correlates Our and which better progression, data the and digital real-world refining the map processes of projects and XXXX, to the and third the and to and aim scale behavioral in of study, psychedelic our neuro other psychiatric will such and perception-altering at benefits and trends patients and outcomes our We model medicine across key clinicians psychotherapy medicine enrolled products effort environment characteristics substances inform could and improve believe aspects outflow the techniques range experience invitation disorders. the enable a the provide rich to all the in and of that delivery of used treatment first understanding activity, for psychotherapies.

to the Overall, these excited Our Halperin collaboration With Dr. Wernli, to exciting early-stage Executive turn and team and our the ahead. that, product for hard call research and out the about into milestones remain these to extremely incredibly activities. Miri advancements value-driving improving our will and research I President, development are discuss we dedicated this advance novel outcomes and approaches worked has we psychiatric to clinic, patients. rolling over

Miri Halperin Wernli

Thank you, Dan.

our the have and and both early the external world. have capabilities internally around through research year, to and organizations sponsored over academic place past with significantly strengthened collaborations we programs, development our the we addition In leading development research in

despite Before many we academic dive psychedelic I advancing into our played institutions landscape, obstacles the the in hurdles. that role to and want have the regulatory highlight ongoing critical collaborations,

mission and improve to unlock the efforts a development proud outcomes treatment field in patient understanding advance pathways new As are new pioneers whose of we brain the health is biopharmaceuticals. to company, modalities with to to and in disorders, join

ongoing projects. specific our to Now

patents include retained and clinical with This with discussing their Hospital trials. worldwide data, LSD was Basel Switzerland. to completed Let program associated at me Under and also partnership, and additional begin this compounds DMT. extended psychedelic two by rights preclinical and compounds, and seven evaluating from Liechti we the collaboration year the to research in Lab our studies as last University data collaboration mescaline as MDMA, includes ongoing XX well exclusive

than the based expands with of preclinical been paper peer-reviewed this coming have accelerating in collaboration between dose-dependent generated in the LSD has clinical demonstrated the The The neuro our Lab Lab and knowledge and in potential of that are invaluable program. number on collected a to inform study evaluating and psychopharmacology rather therapeutic comparing recently past And published substance-dependent. of data research a applications psilocybin psychedelics. future LSD effects psilocybin over out ongoing the the subjects. the of Liechti This data key Our further and our acute utility has UHB patent decade. development drug partnership differences studies healthy the Liechti study

performance, the We neuroplasticity the University response. a system collaboration and quality also benefits with have life of immune the Lab regulation, Cooper’s on markers, research at Masters in quality, mood Netherlands cognitive potential emotional to LSD sleep of evaluate

to Phase was and academic in study progress. ‘XX X in University initiated Our Masters continues QX

and and intellectual on and Compounds partnership The The owned have effect. compounds well-established related will outright acute initial Additionally, and by a current, property MindShift non-perceptual at with we both own and developing pipeline. effects our clinical Switzerland these psychedelic an technology expanding Limited in collaboration be discovery MindMed. drug is ongoing targets Basel, perceptual aimed pharmaceutical on optimization platform, characterizing partnership next-generation properties and/or with with pathogenic

seeking stabilizing the to Lastly, of back on the liposome bio to formulation explore maintaining has will for and number company, with therapeutic development to had effective turn we studies. distribution Utilizing our in showing ongoing to biomedical The target of Israeli proprietary collaboration major the research now to compounds innovative technology of systemic of Rob. derivatives delivery to drug minimize it areas, develop the NxStage a proprietary of to concentrations mitigate of a already brain. delivery improving ibogaine utility therapeutic exposure with collaborating while I technology, a over are a Therapeutics, risk lysosome drug NxStage peripheral application brain-targeted adverse this effects. drug seeks assist benefit compounds impact

Rob Barrow

and Mary. our December now financial quarter year XX, turn for you, We’ll to results Thank fourth ended the fiscal XXXX.

for million available to year will of year compared related XXXX. expenses clinical operating activities million $XX.X due its related were in December $XX.X the $XX.X used our services XX, believes primarily XXXX. $XX.X MindMed development $X.X company net totaling The $X The million December equivalent Internal to its XX, was XX, support of stock-based year to increased expenses period for $XX.X research stock-based key of million cash programs. in personnel ended million technology. increase million, MindMed XX, MM-XXX $X.X XX, requirements of to to the $X.X compared amortization be and research, for ended sufficient meet primarily the million XXXX. XXXX, XXXX. XX, of compensation of and and year million year in million our million XXXX, to of G&A ended to operating $XX.X non-cash had $XX.X cash to December were with as the million clinical ended an million The compared December $XX.X costs professional developed million into growth the an for our and MM-XXX $XX.X in an the its As costs the XXXX, ended million were due R&D expenses $X.X non-cash related XXXX, December in research, XX, same XXXX. the expenses other beyond to to expenses related to for December and expenses. of milestones increase in $XXX.X compared higher primarily increase for expenses of increase in was increase million December cash compensation

to MindMed, compared The year was December organization building world-class XX, huge that an the important in patients December to for has compensation, XXXX. to to were value positioned million the G&A December need which through XXXX, deliver ended deliver shareholders. strides XX, is the ended XXXX a ended we December Overall, million year XX, extraordinary compared significant for $XX.X stock-based to XX, loss pharmaceutical ended $XX.X to been for XXXX, $XX.X for well made expenses million year for our XXXX. and the comprehensive Excluding net million year $XX.X year therapies in

level, all our attract of We incredible be organization very the every for this within more I work I both proud and Advisory Board. of am have our significant incredibly executive outside people, fortunate organization, Scientific of who make and and at with additions been to our team, across within critical achievements top organization talent to grateful the numerous areas our including possible. Board management Directors cannot

XXXX continue of advancing the significant that, and to all With drug here we to our another medicine like growth am MindMed again expect would happy year be being thank for and I as I in take questions. We you digital pipeline. to any today

Operator

first from of ahead. H.C. is Our Trucchio Instructions] [Operator question Patrick Please coming go Wainwright.

Patrick Trucchio

the Thanks. Good morning on and congrats progress. all

on First, few of around around follow-up a MM-XXX, expectations questions dose-optimization trial disorder. the questions couple design X in and Phase made anxiety trial the a

As first, the integration how just just is would last? how XXX well therapy or in person control dose sessions preparation selected? So, is anticipated? expected sessions conducted virtually? what placebo micrograms of be? or long And trial are How be And in many are the the those to then and they anticipated to

Rob Barrow

Great. Thanks much, so Patrick.

to research pharmacokinetic micrograms and characterized and on and micrograms, a colleagues in XX were driven micrograms study XX looked doses. and first pharmacodynamics particular, part our UHB selected of by take the of studies those micrograms, XXX XXX past your which LSD, and So, doses doses recent had range dose at at the looked the question, in at,

and at study, but gives across exposure four approached dose both the plus the those full data, can pivotal key spectrum. breadth have the and also the across look the also into looking of leverage statistical levels, to we select The supports us broad optimize to And need to we allowed PK/PD us a efficacy really placebo preliminary so control, those when the been studies. the using range forward dose dose methodology take

true maximize a micrograms, or these tenfold power, been the So, us also while of of appropriate difference has said, also Yes, include the five lot treatment that was the as we up control roughly dose-optimization have dose appropriate – around of that as therefore, somewhat placebo LSD is to dose this to allows dose sub-perceptual, low Because clinical XX condition. microgram control. dose, That response the the dose in serves exposure range. statistical are both doing to trials. really, as looking leveraging have our from Nonetheless, a we study, We PK/PD there arms, placebo, a in sub-experiential the those placebo you a the of and high XXX at view zero course, to dialogue, we felt the a results. a it placebo including about are control choice of a we dose when the optimization curves of across placebo.

levels range control response move important us a and the and can And to studies looking these pivotal of will we allow single dose at again. so the in placebo into ultimately each dose including the inherently competitor that select to full choose assessing a across

Patrick Trucchio

helpful. That’s be then it’s mentioned the And – or Yes. to would one just it active expected be I session. that was one – think there have

I am of that guess, regulators sessions think how the does the how – determine And should of of And of or done that? a could there kind we those so just is way is how kind I the sessions. some the virtually, view kind have protocol the about you of how therapy kind wondering

Rob Barrow

outcomes. making this research as goes the patient patient explicitly and a in course, education There our by session, and to when but zoom psychotherapy. visits, which to by we protocol. out, a drugs the as is psychotherapeutic think exactly think has psychotherapy, important additional treatment level as Obviously, about administration. the certainly element contextualize wouldn’t care it it’s into as all psychotherapy is the delivering observation that for said, this Yes, are of patients That includes we think for during of psychotherapy in standard the are these I individuals, become which and are role There very digress the two maximizing in is, patients traditionally. class. what a asking, level essential critical are ready this prior – we treatment protocol globally, a oversight dosing you none view of for are there follow-up sure session, you definition in realm, of qualify in we of not the a clinical And of part of then

Patrick Trucchio

so That’s with evaluating X it. compound at what is time? just helpful. if line just be biomarker Phase Got Would tolerability the may just trial ibogaine? that to MM-XXX, give do MM-XXX, data profile And providing or there safety further that on the regarding and confidence I that anticipate one top any release, imaging other you demonstrating more acceptable compared

Rob Barrow

looking one Certainly, that of features the clinical on number based key be and the in liability seems we would results its are with the one cardiovascular for effects. arrhythmic ibogaine to to going risk. be emission at those be That

And along of risk and with we cardiovascular and and did PK profile of safety do the the so MM-XXX. a the tolerability characterization

are So, clinicaltrials.gov. generally described overall, the of kind what on endpoints to clinical going anticipate and be it’s you study from Phase would all X a

about, biomarkers looking not exposure efficacy the CNS activity. So, tolerability, we for to also there to We course, but whatever safety that fully in are and the can clinical we data study. any are at the certainly seeing CNS are confirm and of this potential glean characterize

glean from this comparisons results, we having some of interesting, X at know be a So, I likelihood these in and CNS quite we terms can of in what ibogaine in also what effects. as the see study, about literature the typical the we we think, the of context look will Phase to and really

Patrick Trucchio

much. Thank so helpful. very you That’s Yes.

Rob Barrow

Patrick. Thanks

Operator

Capital. question Our next coming Sepehr of Instructions] is go ahead. from Please Eight Manochehry [Operator

Sepehr Manochehry

patients. progress. expect the mentioned enrolling on you and pre-qualified of and Thanks the regards color currently, you on the you With visibility on XX to think congrats level there I that enrollment? the give do just enrolled patient last subjects? be I is program continued do me you can is to When have some guess

Rob Barrow

Thanks. Yes.

to ADHD at think referring that’s LSD. with have… Yes, moment the the study ongoing we you I are

Sepehr Manochehry

December the announcement. on exactly Yes,

since how then, been wondering enrolled? many Just have

Rob Barrow

yes. Absolutely,

We We a rates current in the studies. readout enrollment, haven’t half made of that study. typically enrollment from from public announce our and second the anticipate XXXX ongoing don’t still we

Sepehr Manochehry

that second correct? is half Sorry, of ‘XX,

Rob Barrow

Correct.

Sepehr Manochehry

Okay.

that thing or the levers it’s you that levers be of translates like in trials, at bit that qualifying conservative some to duration enrollment you of ‘XX the are kind timeline I one with just accelerated these might and What So, can is make there any trial? looking you the in whether But there to to wondering estimate, readout pull first there play more me this little to that be could terms are and just guys place my think of comes would pre-qualifying can six-week late is like is what a mind or that to sites of you a that pull to And point forward? or patients? that thinking? is anything of

Rob Barrow

at to we requirements plans us, enroll to patients for our studies. that in of these are specific substance the of levers to ability fully have It’s certain terms additional with with There the ultimately, see anticipation same the Schedule used X rate working out. beyond of burden the creates this at kind medication – don’t We some And the the in non-controlled already a perhaps you start-up have enroll the need for and available site and enroll definitely to point. any pull fight to those we have announced. of substances wash all do instances. controlled We

we get clinical and So, looking possible. as readouts quickly to trying ensure as always are we

available to place. this of But number on point, options the in have are plan have us. we continuing We at a we

Sepehr Manochehry

are you particular you or in operating is place your that or the that conducting sites any patients Understood. could or through trials, regards it the is do insight give there pre-qualify sources third-parties And and maybe going going of you Xb, have there? pre-qualified or – your Phase to data other partnerships patients of through enrollment the with trial basically into potential

Rob Barrow

at these level. cases, can muddy is Typically, largely – some waters elsewhere from driven peers even efforts site We our driven of can and seen a further. some going have recruitment – enrollment studies for testing that the efforts Yes. recruitment in the actually centralized largely and for that are broader

actually that those recruitment You challenge can screening to patients patients. eligible get get volume patients a to itself actually of become a huge

But do pull our is recruitment patient central where other have their as we level, and and levers we at both we terminology. so can enrollment are go will to layers be rates, that’s And the identify We that. as that we always out patients at to know studies and at having sites multiple that enhance population availability. really the enrollment use of largely site we then rely able we these can outset. than to activities local that always recruit pursuing And a progress, additional

Sepehr Manochehry

at sense. Understood. to, for in you side Xb in – require go? any do That of enough that compound guess there Phase for are the Phase place things, U.S. outside in to there And the is level having certain regards are there, Xb you to jurisdiction, gain like of initiate of those hurdles the purity I any with where the hurdles formulation or you terms or of ready a makes

Rob Barrow

will cleared included our All we the IND CMC be progress. submission. is on was included on be clinical the would package our submission requisite in But and well information IND updating side that certainly required, And that by everything in FDA. was quality ultimately the as we both as and as that

and confident have and on available that very feel materials QX. progress able are will that that materials have we the in the – we we So, study to

Sepehr Manochehry

that the the that know that just there anticipated then regarding one on expect And the the you Is is readout Ketanserin. – near-term question LSD/trip-stopper Awesome. something or… I in

Rob Barrow

subject studies we Studies Studies of progress Hospital that lines and such colleagues University that are and time that as we largely disclosure such publication. out via containing that study. our that, to at with conducted their are come Basel the investigator-initiated as

are data, driven not sponsor the be. trial readouts by at looked as our would a have they we that corporate we While

precise this subject are study university. and be that a year, readout We anticipating lines is from although of going that criteria of the publication the timing to time release to

Sepehr Manochehry

understand, events or I Understood. like some that. things maybe industry key conferences,

for So, we those? will out look

Rob Barrow

Absolutely.

Sepehr Manochehry

you. Thank Awesome.

Rob Barrow

Thanks Sepehr.

Operator

over now MindMed’s concludes for will call. Thank turn comments. you. Barrow? of to question-and-answer CEO, the closing This the back the I portion Mr. Barrow, Rob call

Rob Barrow

for you, And everyone, Thank being thank this you. morning. again, here

a analysts in along our MindMed, who been many made their and our we the the you, including, at I this entire would supportive participants we Before possible has like brain and our very excited I treatment would of to a thank to particular, the future. conclude, families, look to again, way, and disorders, in study time – the forward and people investors, like team and and part also to of to critically reconnecting thank are important it. have our all health be

Operator

Ladies participation. for event. and concludes today’s gentlemen, thank This you your

rest disconnect may webcast logoff lines of and your enjoy your the You the or day.

Mind Medicine (MNMD) 28 Mar 222021 Q4 Earnings call transcript